Natural killer (NK) cell activity has been shown to have potential activity against Ewing's sarcoma (EWS) especially in tumors with low HLA I expression and high NKG2D expression. Two patients with metastatic relapsed and primary metastatic stage IV EWS who had received two courses of high dose chemotherapy with autologous stem cell rescue were transplanted from a haploidentical parental stem cell donor. Patients are alive in ongoing CR for 10.2 and 3.4 years now. Post transplant local second and first relapses were treated successfully in both patients. In vivo IL-2 stimulation not only increased the number and activity of effector cells in one patient but was also associated with severe GvHD. In vitro studies demonstrated high NK cell activity against K562 and relevant activity against EWS cell line A673 post transplant. NK activity was enhanced by cytokine prestimulation as well as by EWS targeting anti-GD2 Ab. Haploidentical hematopoietic stem cell transplantation (HSCT) might contribute to long-term survival by NK cellmediated effect exerted by donor-derived NK cells. Local tumor recurrence was manageable in both high-risk patients indicating systemic immune control preventing subsequent metastasizing. The efficacy of haploidentical HSCT, cytokine application and tumor targeting antibodies for the use of Ab-dependent cellular cytotoxicity needs evaluation in clinical trials.
INTRODUCTION
Patients with localized Ewing's sarcomas (EWS) can be successfully treated with multimodality treatment. Metastatic relapsed or primarily metastatic EWS or rhabdomyosarcoma aged 410 years have a very poor prognosis, despite of intensive chemotherapy. [1] [2] [3] [4] [5] Most patients with extended disease undergo autologous stem cell transplantation during initial therapy. In disease persistence or recurrence, new treatment strategies are needed. The GvL effect represents a widely accepted major component of allogeneic stem cell transplantation, 6 and there is emerging evidence also for a graft versus tumor effect in solid tumors. [7] [8] [9] Over the last three decades, experience on allogeneic transplantation in pediatric patients with rhabdomyosarcoma and EWS has been collected. Most patients were transplanted from matched related or matched unrelated donors. Intensification of conditioning regimen did not result in higher survival rate because of increased death of transplant-related complications. The major cause of death still is relapse followed by transplant-related toxicity, post transplant infections and GvHD. 10, 11 In mismatched haploidentical transplantation, natural killer (NK) cells have been shown to exert significant GvL effects in the presence of KIR ligand incompatibility in GvH direction. 12, 13 In pediatric solid tumors, this has also been observed in a limited number of patients. 8, 14 Moreover, several pediatric solid tumors are characterized by reduced expression of HLA class I qualifying them valid targets for NK cell lysis. 15, 16 Here, we present two patients with relapsed EWS after autologous hematopoietic stem cell transplantation (HSCT) who have undergone an allogeneic haploidentical HSCT as rescue treatment. The antitumor effect of haploidentical HSCT, especially the role of donor-derived haploidentical NK cells, was investigated in the two presented patients.
MATERIALS AND METHODS
Two pediatric patients with metastatic relapsed or primarily metastatic stage IV EWS received a haploidentical HSCT as experimental treatment. Both patients and their representative in law gave informed consent before the conditioning regimen was started. The clinical course and medium-term follow-up of patient no. 
Cytotoxicity assay
Cytolytic activity of patients' peripheral blood mononuclear cells (PBMCs) 19 and healthy donors' CD56 + -isolated NK cells 20 were tested in a 2 h BATDA Europium release assay against K562 (MHC class I-negative erythroleukemia cell line) and A673 (EWS cell line). In healthy donors, the following target cell lines were tested additionally A204, TE671 and AX-OH-1 (rhabdomyosarcoma), GROH-1 and KNOH-1 (primitive neuroectodermal tumor (PNET)), SWOH-1 and PL377 (rhabdoid tumor). Effector cells were stored overnight at 37°C in RPMI 1640 10% human AB serum with and without IL-2 (40 and 1000 IU/mL) and IL-15 (1 ng/mL). NK cell activity was quantified by measuring the intense fluorescence of the Europium TDA chelates using a time-resolved fluorometer (VICTOR from Wallac Oy, PerkinElmer Life Sciences, Waltham, MA, USA) as previously published. 21 Real-time cytotoxicity assay
The direct cytolytic potential and Ab-dependent cellular cytotoxicity of healthy donor PBMCs against TC-71 was analyzed with a xCELLigence RTCA instrument (Acea Biosciences, San Diego, CA, USA) as described recently. 22 
Statistical analysis
For statistical analysis, GraphPad PRISM software Version 5.04 was used. Analyses included Pearson product-moment correlation coefficient of Ag expression and percentage-specific lysis as well as comparison of specific lysis with and without cytokine stimulation using Mann-Whitney nonparametric test. Patient no. 1 (n = 11) and patient no. 2 (n = 3) post transplant donor-derived PBMCs were tested against A673 in a 2 h BATDA cytotoxicity assay in effector to target ratio 20:1 at different times after transplantation. PBMCs were tested with and without 24 h 1000 IU IL-2/mL prestimulation. IL-2-preincubated PBMCs exerted significantly increased lysis compared to PBMCs without cytokine stimulation, n = 14, Po0.0001. Nonparametric Mann-Whitney test was used for statistical analysis.
RESULTS

Conditioning
2 received a conditioning regimen including treosulfan, thiotepa, fludarabine and muromonab. The haploidentical T-cell-depleted graft (CD3/CD19 depleted) with three HLA loci mismatches from his father comprised 9.53E06/kgBW CD34 + stem cells, 27.17E06/ kgBW CD56 + NK cells and 100E03/kgBW CD3 + residual T cells (Table 1) . Mycophenolate was used as post transplant immunosuppression from day − 1 until day +60. The time to an ANC 40.5 × 10 9 /L and to reach independence from platelet substitution was 10 days. Both patients achieved post transplant complete donor chimerism.
Immune reconstitution and GvHD An early wave of donor-derived CD56 + CD3
− NK cells 4350/ μL in both patients was observed within 4 weeks after transplantation, and CD3 + cell count 4100/μL was reached as early as day +74 and +51, respectively (Figures 1a and e) . Patient no. 1 showed only mild grade I skin GvHD in the early post transplant period. Two weeks of low-dose SU IL-2 triggered deteriorating of GvHD which required multimodal treatment including prednisone, cyclosporine, mycophenolate and photochemotherapy (psoralen plus UV-A). Finally GvHD resolved completely under treatment. 17 Patient no. 2 developed neither acute nor chronic GvHD.
Outcome Both patients are alive in enduring CR for 10.2 and 3.4 years. Transplant-related complications included mucositis WHO IV, febrile neutropenia which resolved after appropriate antibiotics and BKV hemorrhagic cystitis in patient no. 2. No fungal infection, veno-occlusive disease, cardiac toxicity or neurotoxicity occurred. In patient no. 1, a late local relapse (3.6 years post haploidentical) leading to incomplete paraplegia again required intensive multimodal therapy including surgery, chemotherapy and consolidation 36 Gy of local irradiation. After this second relapse, no further event occurred and the patient is in ongoing remission. Patient no.
2 experienced a first local relapse in the left humerus and the right femur (0.8 years post haploidentical) with no clinical signs of relapse, detected in routine magnetic resonance imaging whole body scan. Subsequent local irradiation with 50 Gy has facilitated second CR ever since.
Analysis of NK cell-mediated antitumor activity Both patients exerted antitumor activity against NKG2D ligandpositive cell lines K562 (Figures 1b and f) and A673 (Figures 1c and  g ) already in the early post transplant period mediated by donorderived NK cells. The temporal development of cytotoxic activity was measured at various times after transplantation. Significant lysis of ⩾ 10% of both cell lines was detected throughout the observation phase. Prestimulation with IL-2 significantly increased specific lysis (Figures 1d and h) . A statistical comparison of both patients' PBMCs mediated specific lysis of A673 cell line at several times, with and without cytokine stimulation is shown in the Appendix (A673, P o0.0001, n = 14; Supplementary Figure S1) . The best NK cell activity was achieved using a combination of the cytokines IL-2 and IL-15. The mean specific lysis of eight independent experiments of patient no. 1 is shown in Figure 2a . Moreover, the anti-GD2 CH14.18 monoclonal Ab significantly increased the lysis of the EWS cell line TC-71 measured by xCelligence technology (Figure 2b ). TC-71 expresses low HLA I but a remarkable number of GD2 molecules per cell (Figure 2c ). The NKG2D ligands MIC A/B are even higher expressed than in K562 (Figure 2d ). Further characterization of various sarcoma cell lines included a flow cytometric panel of surface molecules relevant for NK cell-cell interaction. Analysis revealed a positive linear correlation of CD58 expression and specific lysis (Figure 2e) . CD2, CD11a, CD50 and CD102 were not expressed on the tested sarcoma cell lines; CD54 as well as CD95 were heterogeneously expressed but did not correlate with specific lysis. 
DISCUSSION
Haploidentical stem cell transplantation has shown efficacy in the treatment of leukemias 23 and a subgroup of patients with solid tumors. 8, 14 Alloreactive GvL and tumor reactions have been shown to be mediated by NK cells and are responsible to reduce relapse rates significantly. 8, 24 Rapid immune reconstitution of NK cells seem to play a key role in the control of minimal residual disease. 25, 26 Both patients presented here with metastatic relapsed or primary metastatic stage IV EWS are generally considered to have very little chance of cure because of fulfilled high-risk criteria. These are presence of multiple bone lesions, primary tumor volume 4200 ml, bone marrow infiltration as well as pulmonary metastasis in patient no. 1. 5 Rapid in vivo expansion of highly functional NK cells in the early post transplant phase are suggestive to have contributed to systemic tumor control. The long-term CR of both patients no. 1 and 2 who experienced second and first relapse, respectively, is even more impressive. The transplanted immune system had failed to control local tumor recurrence but contrariwise seemed to be able to prevent subsequent metastasizing of the EWS. NK cells are involved in tumor surveillance and in contrast to T cells, NK cells exert particularly high antitumor activity against targets with reduced expression of HLA class I, like neuroblastoma and other solid tumors. 27 Post transplant NK cell function in both of our patients showed stable high cytotoxic activity against the standard target cell line K562 and relevant ⩾ 10% activity against A673 EWS cell line. Post transplant antitumor NK cell activity might have contributed to the favorable outcome. In vivo cytokine stimulation using SU IL-2 administration in patient no. 1 significantly increased NK cell number in vivo and activity (Figure 1 ) but has to be balanced carefully because of potential induction of GvHD. 28, 29 Indeed, there is evidence that GvHD can be associated with GvL and also with graft versus tumor effects. 7, 17, 30, 31 The most important NK cell maturating and activating cytokine IL-15 is being evaluated in a clinical trial (NCT01727076) and could be advantageous in terms of NK cell and T cons effector function compared with IL-2, also for not inducing T reg expansion. 32, 33 EWS is a suitable target for NK cells owing to reduced HLA I expression and NKG2D positivity. 4 Further, some EWS do express relevant amount of GD2 making them vulnerable for CH14.18 monoclonal Ab treatment by recruiting NK cells via Ab-dependent cellular cytotoxicity and by C'-dependent cytotoxicity. [34] [35] [36] Both, application of IL-2 and infusion of targeting antibodies are treatment options, being evaluated in clinical trials after allogeneic HSCT to improve NK-mediated post transplant antitumor effects. 37 Accurate characterization of EWS including HLA I, GD2 and CD58 surface Ag expression may help to elucidate candidates suitable and those unsuitable for NK cell-based immunotherapy. [38] [39] [40] Transfer of expanded or activated haploidentical NK cells could be used to enhance antitumor activity and has been shown to be feasible and safe in numerous pilot studies. 41, 42 In conclusion, multimodal treatment of primary metastatic and relapsed metastatic stage IV EWS including haploidentical stem cell transplantation can facilitate long-term remission and survival. Even patients with PR might benefit from the exchange of the immune system. Actually, post transplant local tumor recurrence was cured completely suggesting relevant graft versus tumor effect for systemic tumor control preventing subsequent metastasizing. Further treatment extension of EWS using immunotherapeutical approaches post haploidentical HSCT including CH14.18 monoclonal Ab administration, application of IL-2 and in the future IL-15 as well as NK cell transfer needs evaluation in clinical trials. 
